US 12,145,973 B2
T-cell modulatory multimeric polypeptides and methods of use thereof
Ronald D. Seidel, III, Boston, MA (US); and Rodolfo J. Chaparro, Cambridge, MA (US)
Assigned to Cue Biopharma, Inc., Boston, MA (US)
Filed by Cue Biopharma, Inc., Boston, MA (US)
Filed on Nov. 10, 2023, as Appl. No. 18/388,788.
Application 17/131,104 is a division of application No. 16/812,926, filed on Mar. 9, 2020, granted, now 10,927,158, issued on Feb. 23, 2021.
Application 18/388,788 is a continuation of application No. 18/080,275, filed on Dec. 13, 2022, granted, now 11,851,467.
Application 18/080,275 is a continuation of application No. 17/831,024, filed on Jun. 2, 2022, granted, now 11,530,248, issued on Dec. 20, 2022.
Application 17/831,024 is a continuation of application No. 17/131,104, filed on Dec. 22, 2020, granted, now 11,401,314, issued on Aug. 2, 2022.
Application 16/812,926 is a continuation of application No. 16/741,202, filed on Jan. 13, 2020, abandoned.
Application 16/741,202 is a continuation of application No. 16/462,443, abandoned, previously published as PCT/US2017/067663, filed on Dec. 20, 2017.
Claims priority of provisional application 62/582,132, filed on Nov. 6, 2017.
Claims priority of provisional application 62/555,435, filed on Sep. 7, 2017.
Claims priority of provisional application 62/470,774, filed on Mar. 13, 2017.
Claims priority of provisional application 62/438,272, filed on Dec. 22, 2016.
Prior Publication US 2024/0076344 A1, Mar. 7, 2024
Int. Cl. A61K 9/00 (2006.01); A61K 35/17 (2015.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01); C07K 14/55 (2006.01); C07K 14/74 (2006.01); G01N 33/50 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/55 (2013.01) [A61K 9/0019 (2013.01); A61K 35/17 (2013.01); C07K 14/005 (2013.01); C07K 14/4748 (2013.01); C07K 14/70539 (2013.01); G01N 33/5008 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2319/30 (2013.01)] 20 Claims
 
1. A nucleic acid comprising:
a) a first nucleotide sequence encoding a first polypeptide comprising:
i) a cancer-associated epitope other than a human papillomavirus epitope; and
ii) a β2-microglobulin (β2M) polypeptide;
b) a second nucleotide sequence encoding a second polypeptide comprising:
i) a major histocompatibility complex (MHC) class I HLA-A heavy chain polypeptide;
ii) two copies of a variant IL-2 polypeptide, each copy comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:44, wherein amino acid 16 is other than a His and amino acid 42 is other than a Phe, and wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST; and
iii) an immunoglobulin (Ig) Fc polypeptide.